YOLFTbeta
Genflow Biosciences plc

Genflow Biosciences plc

GENF · LSE · Healthcare / Biotechnology

1.65GBX+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close1.65
Open1.66
Day Range1.60 – 1.70
52-Week Range1.00 – 3.12
Volume62.80K
Market Cap12.49M
P/E (TTM)0.00
Forward P/E0.00
EPS0.00
Dividend Yield0.00%
Beta2.29
50-Day Avg2.01
200-Day Avg2.04

About

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Eric Jean Leire M.D., MBA
  • Employees5
  • Headquarters6 Heddon Street, London, United Kingdom, W1B 4BT, UK
  • Websitehttps://genflowbio.com

Leadership

  • Dr. Eric Jean Leire M.D., MBAFounder, CEO & Executive Director · b. 1958

Financials

Income Statement

Currency: GBP2021-03-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-00169.85K00
Growth (%)-----100.00%-
Cost of Revenue--1301.03K1.20K1.09K
Gross Profit---130-1.03K-1.20K-1.09K
Gross Margin----0.61%--
Operating Expense--1.82M2.03M1.59M2.00M
Operating Income-649.92K-988.10K-1.82M-2.03M-1.59M-2.00M
Operating Margin----1195.26%--
EBITDA-1.09K-988.10K-1.33M-1.80M-1.59M-2.00M
EBITDA Margin----1058.28%--
Net Income-651.01K-988.29K-1.34M-1.63M-1.59M-1.42M
Net Income Margin----958.89%--
R&D93.87K86.04K724.47K960.31K1.15M1.11M
R&D as % of Total Revenue---565.38%--
Interest Expense-99382000
Interest Expense % of Total Revenue---0.00%--

Balance Sheet

Currency: GBP2021-03-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets283.78K276.55K2.62M1.07M385.91K452.39K
Total Liabilities64.80K221.43K250.99K345.74K788.92K1.00M
Total Equity218.98K55.12K2.37M725.91K-403.01K-550.78K
Cash254.23K224.00K2.36M683.97K278.68K111.79K
Net Debt-254.23K-224.00K-2.36M-683.97K-278.68K-111.79K

Cash Flow

Currency: GBP2021-03-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-439.46K-747.38K-1.37M-1.66M-1.08M-1.44M
Investing Cash Flow216.55K198.50K-2.48K-2.44K--
Financing Cash Flow1.96M783.71K3.50M-656.63K1.31M
Capital Expenditure002.48K2.44K05
Free Cash Flow-439.46K-747.38K-1.37M-1.66M-1.08M-1.44M
FCF to OCF100.00%100.00%100.18%100.15%100.00%100.00%

Earnings

Report DateJan 17, 2022Apr 25, 2022Sep 30, 2022Apr 24, 2023Sep 30, 2024Apr 30, 2025Sep 30, 2025
EPS Estimate0.000.000.000.000.000.000.00
EPS Actual0.00-0.020.000.000.000.000.00
Surprise-------
Timing-------

Key Statistics & Ratios

Market Cap12.49M
Enterprise Value12.24M
Trailing P/E0.00
Forward P/E0.00
Price / Sales21.32
Price / Book10.48
EPS0.00
Book Value-0.001
Revenue (TTM)585.61K
Gross Profit (TTM)585.61K
EBITDA-1.10M
Profit Margin-187.87%
Operating Margin-187.78%
Return on Equity-648.46%
Return on Assets-112.92%
Shares Outstanding594.53M
Shares Float325.67M
Beta2.29
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%